Beam, Inc. (BEAM) Misses Q3 EPS by 28c, Revenues Beats

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. PTC
2. PCVX
3. NVDA
4. SPY
5. META
6. MSFT
7. RXO
8. GOOGL
9. GMAB
10. BETR

Go back to Beam, Inc. (BEAM) Misses Q3 EPS by 28c, Revenues Beats

Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results

November 7, 2022 6:30 AM EST

Patient Recruitment Underway in BEACON Clinical Trial of BEAM-101 for Treatment of Sickle Cell Disease as Part of Wave 1 Strategy Execution

IND-enabling Studies Underway for BEAM-301 for Treatment of GSDIa

BEAM-302 Nominated as Development Candidate for Treatment of Alpha-1 Antitrypsin Deficiency; Targeting Durable Gene Correction Designed to Address Both Lung and Liver Disease

New Data Highlighting Enhanced Conditioning Approach for Hematologic Transplant (ESCAPE) to be Presented at ASH

Ended Third Quarter 2022 with $1.1 Billion in Cash, Cash Equivalents and Marketable Securities

CAMBRIDGE,... More